Edwards Lifesciences Free Cash Flow 2010-2025 | EW
Edwards Lifesciences annual/quarterly free cash flow history and growth rate from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Edwards Lifesciences free cash flow for the quarter ending March 31, 2025 was 289.90, a year-over-year.
- Edwards Lifesciences free cash flow for the twelve months ending March 31, 2025 was , a year-over-year.
- Edwards Lifesciences annual free cash flow for 2024 was $0.29B, a 54.9% decline from 2023.
- Edwards Lifesciences annual free cash flow for 2023 was $0.643B, a 33.98% decline from 2022.
- Edwards Lifesciences annual free cash flow for 2022 was $0.974B, a 30.77% decline from 2021.
| Edwards Lifesciences Annual Free Cash Flow |
| 2024 |
289.90 |
| 2023 |
642.80 |
| 2022 |
973.60 |
| 2021 |
1,406.30 |
| 2020 |
647.30 |
| 2019 |
928.50 |
| 2018 |
688.00 |
| 2017 |
832.60 |
| 2016 |
528.30 |
| 2015 |
447.00 |
| 2014 |
942.50 |
| 2013 |
366.00 |
| 2012 |
256.10 |
| 2011 |
235.50 |
| 2010 |
196.20 |
| 2009 |
199.20 |
| Edwards Lifesciences Quarterly Free Cash Flow |
| 2024-12-31 |
289.90 |
| 2024-09-30 |
467.20 |
| 2024-06-30 |
167.30 |
| 2024-03-31 |
-118.80 |
| 2023-12-31 |
642.80 |
| 2023-09-30 |
594.50 |
| 2023-06-30 |
238.30 |
| 2023-03-31 |
252.60 |
| 2022-12-31 |
973.60 |
| 2022-09-30 |
759.70 |
| 2022-06-30 |
509.70 |
| 2022-03-31 |
220.60 |
| 2021-12-31 |
1,406.30 |
| 2021-09-30 |
1,122.50 |
| 2021-06-30 |
651.30 |
| 2021-03-31 |
194.50 |
| 2020-12-31 |
647.30 |
| 2020-09-30 |
360.70 |
| 2020-06-30 |
247.90 |
| 2020-03-31 |
124.90 |
| 2019-12-31 |
928.50 |
| 2019-09-30 |
597.10 |
| 2019-06-30 |
235.90 |
| 2019-03-31 |
-40.70 |
| 2018-12-31 |
688.00 |
| 2018-09-30 |
452.70 |
| 2018-06-30 |
195.50 |
| 2018-03-31 |
108.10 |
| 2017-12-31 |
832.60 |
| 2017-09-30 |
520.60 |
| 2017-06-30 |
252.10 |
| 2017-03-31 |
112.40 |
| 2016-12-31 |
528.30 |
| 2016-09-30 |
390.40 |
| 2016-06-30 |
232.60 |
| 2016-03-31 |
79.40 |
| 2015-12-31 |
447.00 |
| 2015-09-30 |
380.70 |
| 2015-06-30 |
204.20 |
| 2015-03-31 |
52.50 |
| 2014-12-31 |
942.50 |
| 2014-09-30 |
880.70 |
| 2014-06-30 |
886.60 |
| 2014-03-31 |
124.60 |
| 2013-12-31 |
366.00 |
| 2013-09-30 |
272.50 |
| 2013-06-30 |
162.90 |
| 2013-03-31 |
64.30 |
| 2012-12-31 |
256.10 |
| 2012-09-30 |
185.10 |
| 2012-06-30 |
76.90 |
| 2012-03-31 |
-48.70 |
| 2011-12-31 |
235.50 |
| 2011-09-30 |
168.10 |
| 2011-06-30 |
68.30 |
| 2011-03-31 |
1.00 |
| 2010-12-31 |
196.20 |
| 2010-09-30 |
122.40 |
| 2010-06-30 |
40.90 |
| 2010-03-31 |
7.10 |
| 2009-12-31 |
199.20 |
| 2009-09-30 |
151.50 |
| 2009-06-30 |
30.20 |
| 2009-03-31 |
-20.10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED INSTRUMENTS |
$44.472B |
$5.440B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
